A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab